

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
David N. Herndon

Serial No.: 09/901,429

Filed: July 9, 2001

For:  $\beta$ -ADRENERGIC BLOCKADE  
REVERSAL OF CATABOLISM AFTER  
SEVERE BURN

Group Art Unit: 1614

Examiner: Vickie Y. Kim

Atty. Dkt. No.: CLFR:218US

**CERTIFICATE OF FACSIMILE TRANSMISSION**  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted to: Ms Sherry Brinkley, Office of Petitions  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450, facsimile number (571) 273-0025 on the date below:

April 28, 2005  
Date

*Monica A. De La Paz*  
Monica A. De La Paz

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**Office of Petitions**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The Commissioner is authorized to deduct the appropriate fee of \$180.00 from Fulbright & Jaworski Account No.: 50-1212/CLFR:218US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Monica A. De La Paz  
Reg. No. 54,662  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: April 28, 2005

Form PTO-1449 (modified)		Atty. Docket No. CLFR:218US	Serial No. 09/901,429
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant David N. Herndon	
		Filing Date: July 9, 2001	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2001/0056068	12/27/01	Chwalisz <i>et al.</i>	514	21	3/4/98
	A2	6,194,578	2/27/01	Griffith <i>et al.</i>	544	349	7/7/99

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Baron <i>et al.</i> , "Prolonged use of propranolol safely decreases cardiac work in burned children," <i>J. Burn Care Rehabil.</i> , 18:223-227, 1997.
	C2	Breitenstein <i>et al.</i> , "Effects of beta-blockade on energy metabolism following burns," <i>Burns</i> , 16:259-264, 1990.
	C3	Hart <i>et al.</i> , "Anticatabolism after sever burn: synergism between growth hormone and propranolol," Abstract in <i>Surg. Forum</i> , 51:196-197, 2000.
	C4	Herndon <i>et al.</i> , "Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients," <i>Ann. Surg.</i> , 208:484-492, 1988.
	C5	Herndon <i>et al.</i> , "Lipolysis in burned patients is stimulated by the $\beta_2$ -receptor for catecholamines," <i>Arch. Surg.</i> , 129:1301-1305, 1994.
	C6	Mangano <i>et al.</i> , "Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group," <i>N. Engl. J. Med.</i> , 335:1713-1720, 1996.
	C7	Miniffee <i>et al.</i> , "Improved myocardial oxygen utilization following propranolol infusion in adolescents with postburn hypermetabolism," <i>Pediatr. Surg.</i> , 24:806-810, 1989.

25487002.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)